Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Adaptive, Alnylam, Amgen, Ansun, Assembly, Astellas, Aurobindo, Bioaegis, Bioardis, Bionomics, Brii, Capricor, Carterra, Celltrion, Celularity, Cytodyn, Diffusion, Eisai, Ennaid, Evotec, Evqlv, Flexion, Flugen, GSK, Ildong, Incyte, Innate, Innovation, Junshi, Kalos, Kleo, Lee's, Macromoltek, Mateon, Medincell, Modalis, Novartis, Noxopharm, Nuvo, Ocumension, Onxeo, Ostrich, Otsuka, Persephone, Premas, Primmune, Sanbio, Seikagaku, Seneca, Shenogen Pharma, Sirona, Sorrento, Takeda, Ultragenyx, Vaxart, Vir, Viscient, Voltron.
Biopharmas in Asia-Pacific raising money in public or private financings, including: Propanc Biopharma.
The latest global regulatory news, changes and updates affecting biopharma, including: Biotechnology Innovation Organization, Central Drugs Laboratory, Drugs Controller General, EMA, FDA, Gilead Sciences, Health and Human Services, Medicines and Healthcare Products Regulatory Agency, National Institute for Health and Care Excellence, Pfizer Healthcare India, Pharmaceuticals and Medical Devices Agency.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Algernon, Ansun, Apeiron, Cytodyn, Eusa, Hutchison China Meditech, I-Mab, Inflarx, Inovio, Kiniksa, Nanocarrier, Novan, Oncoceutics, Sato, Synairgen, Vanda, VBL.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Applied, Celularity, Cytodyn, Eisai, Faron, Gracell, I-Mab, Mallinckrodt, Mesoblast, Novoteris, Pharmamar, Revive, Takeda.